{Reference Type}: Journal Article
{Title}: A comparison of the TempO-Seq and Affymetrix microarray platform using RTqPCR validation.
{Author}: Wehr MM;Reamon-Buettner SM;Ritter D;Knebel J;Niehof M;Escher SE;
{Journal}: BMC Genomics
{Volume}: 25
{Issue}: 1
{Year}: 2024 Jul 3
{Factor}: 4.547
{DOI}: 10.1186/s12864-024-10586-7
{Abstract}: Next-generation risk assessment relies on mechanistic data from new approach methods, including transcriptome data. Various technologies, such as high-throughput targeted sequencing methods and microarray technologies based on hybridization with complementary probes, are used to determine differentially expressed genes (DEGs). The integration of data from different technologies requires a good understanding of the differences arising from the use of various technologies.To better understand the differences between the TempO-Seq platform and Affymetrix chip technology, whole-genome data for the volatile compound dimethylamine were compared. Selected DEGs were also confirmed using RTqPCR validation. Although the overlap of DEGs between TempO-Seq and Affymetrix was no higher than 37%, a comparison of the gene regulation in terms of log2fold changes revealed a very high concordance. RTqPCR confirmed the majority of DEGs from either platform in the examined dataset. Only a few conflicts were found (11%), while 22% were not confirmed, and 3% were not detected.Despite the observed differences between the two platforms, both can be validated using RTqPCR. Here we highlight some of the differences between the two platforms and discuss their applications in toxicology.